Roche wades deeper into the allogeneic CAR-T field, reserving billions for its next early-stage partner

John Carroll

Editor & Founder

Aayushi Pratap

News Reporter

Roche has taken its next big step into the allogeneic CAR-T field, this time tying up alongside Poseida Therapeutics $PSTX with $220 million in upfront …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roche wades deeper into the allogeneic CAR-T field, reserving billions for its next early-stage partner

John Carroll

Editor & Founder

Aayushi Pratap

News Reporter

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Roche wades deep­er in­to the al­lo­gene­ic CAR-T field, re­serv­ing bil­lions for its next ear­ly-stage part­ner

Editor & Founder

News Reporter

Sign up to read this article for free.

Roche wades deeper into the allogeneic CAR-T field, reserving billions for its next early-stage partner